Cytokinetics' Heart Disease Drug Myqorzo Meets Primary Endpoints in Phase 3 Trial for Genetic Heart Condition

Cytokinetics announced on May 5, 2026 that Myqorzo met dual efficacy endpoints in the Phase 3 ACACIA trial for non-obstructive hypertrophic cardiomyopathy, significantly improving heart failure symptoms and cardiovascular fitness. The drug is already approved for the obstructive form of the inherited heart disorder. Analysts forecast peak sales could reach $5 billion annually if regulators approve the expanded indication.

ACACIA Phase 3 trial results

• ▪The Phase 3 ACACIA clinical trial of Myqorzo achieved dual efficacy goals with statistical significance.
• ▪Cytokinetics' drug Myqorzo significantly improved heart failure symptoms in patients with non-obstructive hypertrophic cardiomyopathy in the Phase 3 ACACIA clinical trial.
• ▪Cytokinetics announced the ACACIA Phase 3 trial results on May 5, 2026.

Non-obstructive HCM indication

• ▪Analysts forecast Myqorzo's peak sales could reach $5 billion annually if the drug is approved for non-obstructive hypertrophic cardiomyopathy.
• ▪The successful outcome of the ACACIA study could greatly expand the number of HCM patients eligible for Myqorzo treatment if cleared by regulators.
• ▪Non-obstructive hypertrophic cardiomyopathy is an inherited heart disorder.

Myqorzo commercial expansion

• ▪Cytokinetics is in the early days of Myqorzo's commercial launch as a treatment for the obstructive form of hypertrophic cardiomyopathy.
• ▪Myqorzo is approved as a treatment for the obstructive form of hypertrophic cardiomyopathy.
• ▪Adam Feuerstein is a senior writer and biotech columnist who authored the article published on May 5, 2026.

1 source